Major depressive disorder, sleep EEG and agomelatine: an open-label study INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY Salva, M. Q., Vanier, B., Laredo, J., Hartley, S., Chapotot, F., Moulin, C., Lofaso, F., Guilleminault, C. 2007; 10 (5): 691-696


This open study evaluates the effect of agomelatine, a melatonergic receptor agonist and 5-HT2C antagonist antidepressant, on sleep architecture in patients suffering from major depressive disorder. Fifteen outpatients with a baseline HAMD score > or = 20 were treated with 25 mg/d agomelatine for 42 d. Polysomographic studies were performed at baseline, day 7, day 14, and day 42. Sleep efficiency, time awake after sleep onset and the total amount of slow-wave sleep (SWS) increased at week 6. The increase of SWS was predominant during the first sleep cycle. The amount of SWS decreased throughout the first four sleep cycles from day 7 and delta ratio increased from day 14 onwards. No change in rapid eye movement (REM) latency, amount of REM or REM density was observed and agomelatine was well tolerated. In conclusion agomelatine improved sleep continuity and quality. It normalized the distribution of SWS sleep and delta power throughout the night.

View details for DOI 10.1017/S1461145707007754

View details for Web of Science ID 000250063600012

View details for PubMedID 17477886